Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.
|
17003774 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Chromatin regulators ANCCA and EZH2 are overexpressed in prostate cancer and play crucial roles in androgen-stimulated and castration-refractory prostate tumor growth and survival.
|
23038103 |
2013 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
|
15817459 |
2005 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
|
21903722 |
2011 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
|
16963837 |
2006 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
|
18637271 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
|
18159594 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Loss of Skp2 resulted in a striking decrease of Ezh2 levels in Pten/Trp53 double-null MEFs and in prostate tumors of Pten/Trp53 double-null mutant mice.
|
27869166 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Polycomb Group protein enhancer of zeste 2 (EZH2) was found to be overexpressed in metastatic prostate tumors, and is considered an excellent candidate for such a biomarker.
|
20087897 |
2010 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
|
17134822 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
|
17237810 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
|
16575874 |
2006 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The polycomb group protein EZH2 is involved in progression of prostate cancer.
|
12374981 |
2002 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.
|
18095286 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines.
|
22330138 |
2012 |